A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip

Sponsor
Genzyme, a Sanofi Company (Industry)
Overall Status
Completed
CT.gov ID
NCT00131326
Collaborator
(none)
32
29

Study Details

Study Description

Brief Summary

This is a clinical study to investigate the safety and efficacy of Synvisc and Depo-Medrol in treating patients with osteoarthritis (OA) of the hip.

Condition or Disease Intervention/Treatment Phase
  • Device: Synvisc (hylan G-F 20)
Phase 3

Study Design

Study Type:
Interventional
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double
Primary Purpose:
Treatment
Study Start Date :
Nov 1, 2003
Study Completion Date :
Apr 1, 2006

Outcome Measures

Primary Outcome Measures

  1. Pain relief []

Eligibility Criteria

Criteria

Ages Eligible for Study:
35 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with symptomatic osteoarthritis pain of hip
Exclusion Criteria:
  • Patients with current or prior conditions or treatment that would impede measurement of efficacy and safety

Contacts and Locations

Locations

Site City State Country Postal Code
1 Alabama Clinical Therapeutics Birmingham Alabama United States 35235
2 John Higginbotham, MD Sports Medicine Huntsville Alabama United States 35802
3 Affiliated Orthopedic Specialists Scottsdale Arizona United States 85260
4 Arkansas Orthopaedic Specialists Little Rock Arkansas United States 72205
5 Cedars-Sinai Orthopedic Center Los Angeles California United States 90048
6 Jackson Arthritis Center Oakland California United States 94609
7 Orthopedic Medical Group San Diego California United States 92123
8 Orthopedic Specialists of Tamp Bay, P.A. Clearwater Florida United States 33756
9 Orthopedic Institute at Mercy Hospital Miami Florida United States 33133
10 Hughston Sports Medicine Foundation Columbus Georgia United States 31909
11 Idaho Arthritis & Osteoporosis Center Meridian Idaho United States 83642
12 Northwestern Orthopaedic Institute Chicago Illinois United States 60611
13 Illinois Bone and Joint Institute, Ltd. Morton Grove Illinois United States 60053
14 David S. Tearse, MD (Private Practice) Cedar Rapids Iowa United States 52403
15 Kansas City Orthopedic Institute Leawood Kansas United States 66211
16 Bluegrass Orthopaedics Lexington Kentucky United States 40509
17 Orthopedic Specialists of Louisiana Shreveport Louisiana United States 71101
18 Maryland General Hospital Baltimore Maryland United States 21201
19 Family Orthopedic Associates Flint Michigan United States 48507
20 Washington University School of Medicine Saint Louis Missouri United States 63110
21 UMDNJ-RWJ University Orthopedic Group New Brunswick New Jersey United States 08901
22 Hospital for Special Surgery New York New York United States 10021
23 Health Research Institute Oklahoma City Oklahoma United States 73109
24 Orthopedic Center for Joint Replacement & Sports Medicine Grants Pass Oregon United States 97527
25 Altoona Center for Clinical Research Duncansville Pennsylvania United States 16635
26 Lancaster Orthopedic Group Lancaster Pennsylvania United States 17601
27 Allegheny Orthopedic Associates Pittsburgh Pennsylvania United States 15212
28 Conway Medical Center Conway South Carolina United States 29526
29 Chattanooga Center for Sports Chattanooga Tennessee United States 37404
30 Gurdev Gill, MD (Private Practice) Lubbock Texas United States 79410
31 Carilion Bone and Joint Center, Vinton Orthopedic Surgery Vinton Virginia United States 24179
32 Arthritis Northwest Seattle Washington United States 98166-2967

Sponsors and Collaborators

  • Genzyme, a Sanofi Company

Investigators

  • Study Director: Medical Monitor, Genzyme, a Sanofi Company

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00131326
Other Study ID Numbers:
  • SYNV-004-02
First Posted:
Aug 18, 2005
Last Update Posted:
Jul 31, 2017
Last Verified:
Jul 1, 2017

Study Results

No Results Posted as of Jul 31, 2017